GI division

Quote







Mirikizumab data is strong. Will compete with small molecule oral options but Buy & Bill biz model will be very attractive to offices. Medicare Part B coverage of Infusion Med also a huge advantage. If leadership lets the field do their job, could be a stellar opportunity
 


Mirikizumab data is strong. Will compete with small molecule oral options but Buy & Bill profit model and Part B Medicare Coverage offer lots of advantages. If leadership stays out of the day to day field Ops, could be a great gig/great launch with multiple additional indications to follow
 


anonymous said:
Mirikizumab data is strong. Will compete with small molecule oral options but Buy & Bill profit model and Part B Medicare Coverage offer lots of advantages. If leadership stays out of the day to day field Ops, could be a great gig/great launch with multiple additional indications to follow
Click to expand...
Buy and Bill! How do you people sleep at night?
 






anonymous said:
Give it away? A classic mischaracterization, indeed, a false dichotomy of the problem of Buy and Bill.

I should not be surprised that the intellectuals on this board would perform differently.
Click to expand...

since you’re such an intellectual, and an expert on all things health care, why don’t you tell us what your business model would be. What exactly do you propose?
 


I think the McKesson post sums it up. It looks like they are there to help a practice "...maintain the integrity of the drug..."

Well isn't that special? It is very comforting to know that McKesson is here to help and in the process make just a minuscule profit.

The pros & cons of the "buy and bill" model of pharmaceutical distribution: What's appropriate for your practice?

How about the shenanigans for insulin pricing? Oh, that's right, the net price has decreased because of rebates. Gee thanks, Uncle Eli. If so, then how is the system passing along a larger total cost of insulin to the patient?

The whole system is broken and should be torn asunder, but Buy and Bill is pathetic. Just ask your manager to have the market research team share the qualitative transcripts, not the sanitized BS version they tout.
 

















Write your reply...
Top Bottom
Back
Quote